Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
This phase I/II trial studies the side effects and the best dose of brentuximab vedotin when given together with gemcitabine hydrochloride and to see how well they work in treating younger patients with relapsed or refractory Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving brentuximab vedotin together with gemcitabine hydrochloride may kill more cancer cells
Recurrent Adult Hodgkin Lymphoma
Recurrent/Refractory Childhood Hodgkin Lymphoma
Drug: brentuximab vedotin
Drug: gemcitabine hydrochloride
Other: laboratory biomarker analysis
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase 1/2 Study of Brentuximab Vedotin (SGN35, IND# 117117) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma|
- MTD of brentuximab vedotin in combination with gemcitabine hydrochloride defined as the maximum dose at which fewer than one-third of patients experience DLT as assessed by NCI CTCAE v 4.0 (Part A) [ Time Frame: Up to 21 days ] [ Designated as safety issue: Yes ]
- Incidence of adverse events graded according to NCI CTCAE v4.0 (Part A) [ Time Frame: Up to 5 years ] [ Designated as safety issue: Yes ]
- CR rate (Part B) [ Time Frame: At 12 weeks ] [ Designated as safety issue: No ]
- Disease response (Part A) [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]Reported descriptively.
- ORR (Part B) [ Time Frame: At 12 weeks ] [ Designated as safety issue: No ]
- Toxicity as assessed by NCI CTCAE version 4.0 (Part B) [ Time Frame: Up to 30 days after completion of study treatment ] [ Designated as safety issue: Yes ]
|Study Start Date:||January 2013|
|Estimated Primary Completion Date:||October 2015 (Final data collection date for primary outcome measure)|
Experimental: Treatment (brentuximab vedotin, gemcitabine hydrochloride)
Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 courses in the absence of disease progression or unacceptable toxicity.
Drug: brentuximab vedotin
Other Names:Drug: gemcitabine hydrochloride
Other Names:Other: laboratory biomarker analysis
Optional correlative studies
I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of brentuximab vedotin in combination with gemcitabine (gemcitabine hydrochloride) administered every three weeks to children with relapsed or primary refractory Hodgkin lymphoma (HL).
II. To define and describe the toxicities of brentuximab vedotin in combination with gemcitabine administered on this schedule.
III. To determine the complete response (CR) rate after treatment with four cycles of gemcitabine with brentuximab vedotin among patients with relapsed or refractory HL.
I. To preliminarily define the antitumor activity of brentuximab vedotin in combination with gemcitabine within the confines of a Phase 1 study.
II. To describe the overall response rate (ORR) after 4 cycles of therapy among patients with relapsed or refractory HL.
III. To describe the proportion of patients with HL able to mobilize an adequate yield of cluster of differentiation (CD) 34+ stem cells after gemcitabine with brentuximab vedotin.
IV. To describe the relationship between disease response among patients with HL and changes in thymus and activation-regulated chemokine (TARC) during treatment, and to determine if specific micro ribonucleic acid (miRNA) profiles correlate with response to treatment.
V. To describe the frequency of the FcγRIIIa-158 V/F polymorphism among patients who experience pulmonary toxicity on this protocol.
OUTLINE: This is a dose-escalation study of brentuximab vedotin.
Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment patients are followed up every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years.
|United States, Alabama|
|Children's Hospital of Alabama||Recruiting|
|Birmingham, Alabama, United States, 35233|
|Contact: Joseph G. Pressey 205-934-0309|
|Principal Investigator: Joseph G. Pressey|
|United States, California|
|COG Phase I Consortium||Not yet recruiting|
|Arcadia, California, United States, 91006-3776|
|Contact: Peter D. Cole 718-741-2342 Peter.Cole@Einstein.YU.edu|
|Principal Investigator: Peter D. Cole|
|Children's Hospital and Research Center at Oakland||Recruiting|
|Oakland, California, United States, 94609-1809|
|Contact: Carla B. Golden 510-450-7600|
|Principal Investigator: Carla B. Golden|
|Lucile Packard Children's Hospital Stanford University||Recruiting|
|Palo Alto, California, United States, 94304|
|Contact: Neyssa M. Marina 650-498-7061 email@example.com|
|Principal Investigator: Neyssa M. Marina|
|United States, Indiana|
|Riley Hospital for Children||Recruiting|
|Indianapolis, Indiana, United States, 46202|
|Contact: James M. Croop 317-274-2552|
|Principal Investigator: James M. Croop|
|United States, Missouri|
|Washington University School of Medicine||Recruiting|
|Saint Louis, Missouri, United States, 63110|
|Contact: Robert J. Hayashi 800-600-3606 firstname.lastname@example.org|
|Principal Investigator: Robert J. Hayashi|
|United States, Pennsylvania|
|Children's Hospital of Philadelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Elizabeth Fox 215-590-2810|
|Principal Investigator: Elizabeth Fox|
|Principal Investigator:||Peter Cole||COG Phase I Consortium|